Results 121 to 130 of about 19,002 (159)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion

Indian Journal of Ophthalmology, 2015
Jay Chhablani
doaj   +1 more source

Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion

Indian Journal of Ophthalmology, 2015
Alok Sen, Ashish Mitra, Pawan Puneet Malhotra, Sonal Gupta   +3 more
doaj   +1 more source

374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer, 2021
Howard Streicher, Michael Manos, Philippe Bedard, Osama Rahma, Andrew Brohl, Kevin Tyan, Scott Rodig, Daniel Renouf, Emma Hathaway, Rachel Cunningham   +9 more
doaj   +1 more source

Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. [PDF]

Oncotarget, 2017
Lu CS, Lin JK, Chen WS, Lin TC, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Teng HW.   +11 more
europepmc   +1 more source

Preclinical Investigations of Intravitreal Ziv-Aflibercept

Ophthalmic Surgery Lasers and Imaging Retina, 2014
BACKGROUND AND OBJECTIVE: To investigate the retinal safety of intravitreal (IVT) ziv-aflibercept in rabbits. MATERIALS AND METHODS: Eighteen rabbits were given an IVT injection of ziv-aflibercept (25 mg/mL) or aflibercept (40 mg/mL) and examined by funduscopy, electroretinography ...
Michel Eid Farah, João de Oliveira Dias, Eduardo Buchele Rodrigues   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Intravitreal Ziv-Aflibercept: A Comprehensive Review

Seminars in Ophthalmology, 2019
Background: Age-related macular degeneration is the leading cause of blindness in adults over the age of 50 in the United States of America. Neovascular age-related macular degeneration (nAMD) is sight-threatening, but can be treated by three currently utilized, intravitreally administered drugs: aflibercept, bevacizumab, and ranibizumab.
Daniel Barmas-Alamdari, Haley D'Souza, Kapil G Kapoor   +2 more
exaly   +3 more sources

Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate

International Journal of Biological Macromolecules, 2021
Ziv-aflibercept (aflibercept) is a recombinant fusion protein which combines the portions of human vascular endothelial growth factor receptors extracellular domains fused to the Fc portion of human IgG1. It is a highly sialylated glycoprotein with 5 N-glycosylation sites.
Qing Li, Huarong Xu, Yanhong Wang
exaly   +3 more sources

Long-term safety and efficacy of ziv-aflibercept in retinal diseases [PDF]

British Journal of Ophthalmology, 2017
To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept.Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three ...
Ahmad M Mansour, Mohammed Ashraf, Chintan J Dedhia, Abdulrazzak Charbaji, Ahmed A R Souka, Jay Chhablani   +5 more
openaire   +3 more sources

INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA

Retina, 2016
Diabetic macular edema is the leading cause of blindness in young adults in developed countries. Beyond metabolic control, several therapies have been studied such as laser treatment and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor drugs.
Gabriel Costa de, Andrade, João Rafael de Oliveira, Dias, André, Maia, Michel Eid, Farah, Carsten H, Meyer, Eduardo Büchele, Rodrigues   +5 more
openaire   +3 more sources